236 related articles for article (PubMed ID: 21784652)
1. Biosimilars and non-innovator biotherapeutics in India: an overview of the current situation.
Malhotra H
Biologicals; 2011 Sep; 39(5):321-4. PubMed ID: 21784652
[TBL] [Abstract][Full Text] [Related]
2. Summary of the diverse situation of similar biotherapeutic products in the selected countries (August 2010).
Kang HN
Biologicals; 2011 Sep; 39(5):304-7. PubMed ID: 21880507
[TBL] [Abstract][Full Text] [Related]
3. Regulatory guidelines for biosimilars in Malaysia.
Abas A
Biologicals; 2011 Sep; 39(5):339-42. PubMed ID: 21784655
[TBL] [Abstract][Full Text] [Related]
4. Current development in regulation of similar biotherapeutic products in Brazil.
Castanheira LG; Barbano DB; Rech N
Biologicals; 2011 Sep; 39(5):308-11. PubMed ID: 21868247
[TBL] [Abstract][Full Text] [Related]
5. Concept of biosimilar products in Jordan.
Haddadin RD
Biologicals; 2011 Sep; 39(5):333-5. PubMed ID: 21873079
[TBL] [Abstract][Full Text] [Related]
6. China's perspective on similar biotherapeutic products.
Liang C; Wang J
Biologicals; 2011 Sep; 39(5):312-6. PubMed ID: 21924622
[TBL] [Abstract][Full Text] [Related]
7. The regulatory framework for similar biotherapeutic products in Cuba.
Hechavarría Núñez Y; Pérez Massipe RO; Orta Hernández SD; Muñoz LM; Jacobo Casanueva OL; Pérez Rodríguez V; Domínguez Morales RB; Pérez Cristiá RB
Biologicals; 2011 Sep; 39(5):317-20. PubMed ID: 21930393
[TBL] [Abstract][Full Text] [Related]
8. Towards regulation of similar biotherapeutic products: Thailand's perspective.
Thanaphollert P; Tungsanga K
Biologicals; 2011 Sep; 39(5):346-7. PubMed ID: 21917474
[TBL] [Abstract][Full Text] [Related]
9. An Indian manufacturer's perspective for harmonization of guidelines for similar biotherapeutic products.
Babu PV
Biologicals; 2011 Sep; 39(5):300-3. PubMed ID: 21816621
[TBL] [Abstract][Full Text] [Related]
10. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
Ahmed I; Kaspar B; Sharma U
Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
[TBL] [Abstract][Full Text] [Related]
11. Biosimilars--global issues, national solutions.
Knezevic I; Griffiths E
Biologicals; 2011 Sep; 39(5):252-5. PubMed ID: 21924623
[TBL] [Abstract][Full Text] [Related]
12. Regulatory guideline for biosimilar products in Korea.
Suh SK; Park Y
Biologicals; 2011 Sep; 39(5):336-8. PubMed ID: 21784653
[TBL] [Abstract][Full Text] [Related]
13. Current regulatory and scientific considerations for approving biosimilars in Iran.
Hadavand N; Valadkhani M; Zarbakhsh A
Biologicals; 2011 Sep; 39(5):325-7. PubMed ID: 21873077
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of similar biotherapeutic products (SBPs): scientific principles and their implementation.
Knezevic I
Biologicals; 2011 Sep; 39(5):256-61. PubMed ID: 21907589
[TBL] [Abstract][Full Text] [Related]
15. Registration of similar biological products--Singapore's approach.
Poh J; Tam KT
Biologicals; 2011 Sep; 39(5):343-5. PubMed ID: 21783381
[TBL] [Abstract][Full Text] [Related]
16. Recombinant drug development, regulation, and commercialization: an Indian industry perspective.
Sahoo N; Manchikanti P
BioDrugs; 2011 Apr; 25(2):105-13. PubMed ID: 21230010
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of similar biotherapeutic products: scientific and regulatory challenges.
Griffiths E; Thorpe R; Wadhwa M; Sohn Y
Biologicals; 2011 Sep; 39(5):249. PubMed ID: 21925898
[No Abstract] [Full Text] [Related]
18. Development and regulation of biosimilars: current status and future challenges.
Tsiftsoglou AS; Ruiz S; Schneider CK
BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
[TBL] [Abstract][Full Text] [Related]
19. [Biosimilars--opportunity or threat?].
Swierkot J
Wiad Lek; 2013; 66(2 Pt 2):200-5. PubMed ID: 25775818
[TBL] [Abstract][Full Text] [Related]
20. Biosimilars: opportunity or cause for concern?
Roger SD; Mikhail A
J Pharm Pharm Sci; 2007; 10(3):405-10. PubMed ID: 17727803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
